TP53 and rhabdoid tumor: The siRNA-mediated RPL11 knockdown in p53 wild malignant rhabdoid tumor JMU-RTK-2 cells decreased sensitivity to all topoisomerase inhibitors, including ellipticine (Topo II inhibitor), etoposide (Topo II inhibitor), and topotecan (Topo I inhibitor), compared with scramble siRNA-transfected cells (Figure 1A–C).